Evolus Inc.

9.75+0.2800+2.96%Vol 323.63K1Y Perf 29.02%
Dec 1st, 2023 16:00 DELAYED
BID9.43 ASK9.95
Open9.47 Previous Close9.47
Pre-Market- After-Market9.52
 - -  -0.23 -2.36%
Target Price
16.43 
Analyst Rating
Strong Buy 1.20
Potential %
68.51 
Finscreener Ranking
+     38.22
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
+     35.16
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
+     28.70
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
65.06 
Earnings Rating
Sell
Market Cap557.22M 
Earnings Date
7th Nov 2023
Alpha0.01 Standard Deviation0.27
Beta1.58 

Today's Price Range

9.349.78

52W Range

6.5111.49

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-1.66%
1 Month
23.79%
3 Months
-4.44%
6 Months
9.23%
1 Year
29.02%
3 Years
158.04%
5 Years
-36.70%
10 Years
-

TickerPriceChg.Chg.%
EOLS9.750.28002.96
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
Financial StrengthValueIndustryS&P 500US Markets
1.70
2.30
0.71
2.55
-11.00
Leverage Ratio 4.40
ProfitabilityValueIndustryS&P 500US Markets
58.20
-52.10
-49.00
-
-58.35
RevenueValueIndustryS&P 500US Markets
104.97M
1.87
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.26-0.260.00
Q02 2023-0.26-0.28-7.69
Q01 2023-0.17-0.24-41.18
Q04 2022-0.18-0.19-5.56
Q03 2022-0.31-0.36-16.13
Q02 2022-0.28-0.42-50.00
Q01 2022-0.46-0.3132.61
Q04 2021-0.41-0.3319.51
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.18-50.00Negative
12/2023 FY-0.81-58.82Negative
3/2024 QR-0.1382.89Positive
12/2024 FY-0.58--
Next Report Date-
Estimated EPS Next Report-0.25
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume323.63K
Shares Outstanding57.15K
Shares Float41.61M
Trades Count5.50K
Dollar Volume3.13M
Avg. Volume499.22K
Avg. Weekly Volume352.60K
Avg. Monthly Volume664.60K
Avg. Quarterly Volume480.45K

Evolus Inc. (NASDAQ: EOLS) stock closed at 9.47 per share at the end of the most recent trading day (a -0.53% change compared to the prior day closing price) with a volume of 535.60K shares and market capitalization of 557.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 125 people. Evolus Inc. CEO is David Moatazedi.

The one-year performance of Evolus Inc. stock is 29.02%, while year-to-date (YTD) performance is 26.1%. EOLS stock has a five-year performance of -36.7%. Its 52-week range is between 6.51 and 11.49, which gives EOLS stock a 52-week price range ratio of 65.06%

Evolus Inc. currently has a PE ratio of -5.50, a price-to-book (PB) ratio of 15.03, a price-to-sale (PS) ratio of 4.26, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -38.94%, a ROC of -67.15% and a ROE of -125.45%. The company’s profit margin is -58.35%, its EBITDA margin is -49.00%, and its revenue ttm is $104.97 Million , which makes it $1.87 revenue per share.

Of the last four earnings reports from Evolus Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Evolus Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Evolus Inc. is Strong Buy (1.2), with a target price of $16.43, which is +68.51% compared to the current price. The earnings rating for Evolus Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evolus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evolus Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 47.16, ATR14 : 0.42, CCI20 : 72.28, Chaikin Money Flow : -0.04, MACD : 0.35, Money Flow Index : 41.90, ROC : 18.38, RSI : 61.45, STOCH (14,3) : 76.55, STOCH RSI : 0.00, UO : 43.78, Williams %R : -23.45), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evolus Inc. in the last 12-months were: Alphaeon 1 Llc (Sold 1 850 000 shares of value $15 540 000 ), Avelar Rui (Sold 14 906 shares of value $126 254 ), Beaver Sandra (Sold 3 178 shares of value $30 827 ), David Moatazedi (Sold 70 321 shares of value $595 548 ), Inc. Medytox (Sold 2 224 554 shares of value $19 002 799 ), Moatazedi David (Sold 70 321 shares of value $595 619 ), Rui Avelar (Sold 14 906 shares of value $126 237 ), Vikram Malik (Buy at a value of $1 296 505)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
4 (80.00 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
1 (20.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.20
Strong Buy
1.20
Strong Buy
1.20

Evolus Inc.

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.

CEO: David Moatazedi

Telephone: +1 949 284-4555

Address: 520 Newport Center Drive, Newport Beach 92660, CA, US

Number of employees: 125

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

56%44%

 

News

Stocktwits